Innovative Oxygen Technology Hemotek's flagship product, Ox66®, is a unique soluble oxygen powder that delivers oxygen in a non-gaseous, powdered form, positioning the company at the forefront of oxygen therapeutics innovation with significant potential in medical, health, and wellness markets.

Strategic Medical Partnerships The company has established a long-term licensing partnership with Baylor University since 2013, indicating strong academic collaborations and validation, which can be leveraged to expand licensing, research, and clinical development opportunities.

Market Readiness & FDA Pathway Ox66® has undergone ten years of testing in various markets and is currently progressing toward FDA approval, creating a critical window for engaging with healthcare providers, medical centers, and regulatory bodies for potential early adoption.

Growing Revenue Range With estimated revenues between 1 million and 10 million USD and a focused product pipeline, there are opportunities to target niche segments such as hospitals, clinics, and research institutions for initial sales and strategic partnerships.

Technology & Digital Presence Utilizing advanced tech stacks including AWS, PWA, and JSON-LD, Hemotek is well-positioned to enhance its digital outreach, data management, and e-commerce capabilities, opening avenues for direct sales, educational campaigns, and investor engagement.